Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 90

Results For "SEC"

2377 News Found

India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal
Digitisation | September 02, 2023

India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal

Robots make it to the healthcare conference panel, reflecting the future potential of technology


USFDA delegation visits Amneal Pharmaceutical facility in Matoda
News | September 02, 2023

USFDA delegation visits Amneal Pharmaceutical facility in Matoda

Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities


Jupiter Life Line Hospitals’ IPO to open on Sept. 6
News | September 02, 2023

Jupiter Life Line Hospitals’ IPO to open on Sept. 6

Sets price band at ?695 to ?735 per Equity Share


USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
Drug Approval | September 01, 2023

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia


Elekta and IAEA partner to improve access to cancer care in underserved countries
Healthcare | September 01, 2023

Elekta and IAEA partner to improve access to cancer care in underserved countries

Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden


European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ
Drug Approval | August 30, 2023

European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ

KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population


Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
News | August 30, 2023

Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales

Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion


BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Diagnostic Center | August 29, 2023

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year